Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Empresa Reclamada
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions leer más
Overall, I think that my experience has been good, but we run full tilt, then stop, then full tilt, then stop. There is no constant. I wish the company would invest in the future and become a beginning to end pharm company instead of only thinking about clinical/commercial.
¿Qué son algunas de las mejores cosas de tu equipo?
Overall, my team is easy to work with and friendly.
Revisión
¿Qué va mal y cómo puede mejorarse?
There is nothing coming up behind our current compounds. We need some investment in the future or we will turn into a one and done company.
Revisión
¿Qué necesita mejorar el equipo directivo?
We have no pipeline outside of compounds already known. We have very little science outside of the clinical arena. We have no ability or plan to do new med chem or look at other compounds that has been commumicated.
Revisión
Other Employee Reviews for Karyopharm Therapeutics
×